Saginaw Valley Med Res Group
Welcome,         Profile    Billing    Logout  
 4 Trials 
8 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Wagner, Andrew A
MOTION, NCT05059262 / 2020-004883-25: Study of Vimseltinib for Tenosynovial Giant Cell Tumor

Active, not recruiting
3
123
Europe, Canada, US, RoW
Vimseltinib, DCC-3014, Placebo
Deciphera Pharmaceuticals, LLC, Deciphera Pharmaceuticals, LLC
Tenosynovial Giant Cell Tumor, Pigmented Villonodular Synovitis, Giant Cell Tumor of Tendon Sheath, Tenosynovial Giant Cell Tumor, Diffuse, Tenosynovial Giant Cell Tumor, Localized
08/23
07/26
NCT01207492: Nilotinib in Patients With Relapsed or Metastatic Pigmented Villonodular Synovitis/Tenosynovial Giant Cell Tumor/Diffuse-Type Giant Cell Tumor

Active, not recruiting
2
17
US
nilotinib
Andrew J. Wagner, MD, PhD, Brigham and Women's Hospital, Massachusetts General Hospital, Novartis
Pigmented Villonodular Synovitis, Diffuse-type Giant Cell Tumor, Tenosynovial Giant Cell Tumor
04/14
07/26
ChonDRAgon, NCT04950075: Study of INBRX-109 in Conventional Chondrosarcoma

Recruiting
2
201
Europe, US, RoW
INBRX-109, Placebo
Inhibrx Biosciences, Inc
Conventional Chondrosarcoma
09/25
12/26
NCT06208748: SARC044: a Phase II Trial of Bezuclastinib in Combination with Sunitinib in Patients with GIST

Recruiting
2
40
US
Bezuclastinib in combination with sunitinib
Sarcoma Alliance for Research through Collaboration, Cogent Biosciences, Inc., Dana-Farber Cancer Institute, The Life Raft Group
Gastrointestinal Stromal Tumors, GIST
06/26
06/27
NCT03604783: Phase 1, First-in-human Study of Oral TP-1287 in Patients with Advanced Solid Tumors

Terminated
1
74
US
TP-1287
Sumitomo Pharma America, Inc.
Advanced Solid Tumors, Sarcoma, Ewing Sarcoma, Dedifferentiated Liposarcoma, Synovial Sarcoma
01/24
01/24
FHD-609-C-001, NCT04965753 / 2021-001488-25: FHD-609 in Subjects With Advanced Synovial Sarcoma or Advanced SMARCB1-Loss Tumors

Terminated
1
55
Europe, US
FHD-609
Foghorn Therapeutics Inc., Foghorn Therapeutics Inc.
Advanced Synovial Sarcoma
12/23
12/23
PASS, NCT00756665: Prostate Active Surveillance Study

Recruiting
N/A
3000
Canada, US
University of Washington, Canary Foundation, Early Detection Research Network
Prostatic Neoplasms
09/29
09/32
NCT06732440: Subthreshold Vestibular Stimulation as a Strategy for Rehabilitation

Not yet recruiting
N/A
30
US
Subthreshold Vestibular Conditioning, Balance Training
Creighton University, National Institute on Deafness and Other Communication Disorders (NIDCD)
Vestibular Hypofunction, Bilateral Vestibular Hypofunction, Presbyvestibulopathy
12/26
12/26
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Wagner, Andrew A
MOTION, NCT05059262 / 2020-004883-25: Study of Vimseltinib for Tenosynovial Giant Cell Tumor

Active, not recruiting
3
123
Europe, Canada, US, RoW
Vimseltinib, DCC-3014, Placebo
Deciphera Pharmaceuticals, LLC, Deciphera Pharmaceuticals, LLC
Tenosynovial Giant Cell Tumor, Pigmented Villonodular Synovitis, Giant Cell Tumor of Tendon Sheath, Tenosynovial Giant Cell Tumor, Diffuse, Tenosynovial Giant Cell Tumor, Localized
08/23
07/26
NCT01207492: Nilotinib in Patients With Relapsed or Metastatic Pigmented Villonodular Synovitis/Tenosynovial Giant Cell Tumor/Diffuse-Type Giant Cell Tumor

Active, not recruiting
2
17
US
nilotinib
Andrew J. Wagner, MD, PhD, Brigham and Women's Hospital, Massachusetts General Hospital, Novartis
Pigmented Villonodular Synovitis, Diffuse-type Giant Cell Tumor, Tenosynovial Giant Cell Tumor
04/14
07/26
ChonDRAgon, NCT04950075: Study of INBRX-109 in Conventional Chondrosarcoma

Recruiting
2
201
Europe, US, RoW
INBRX-109, Placebo
Inhibrx Biosciences, Inc
Conventional Chondrosarcoma
09/25
12/26
NCT06208748: SARC044: a Phase II Trial of Bezuclastinib in Combination with Sunitinib in Patients with GIST

Recruiting
2
40
US
Bezuclastinib in combination with sunitinib
Sarcoma Alliance for Research through Collaboration, Cogent Biosciences, Inc., Dana-Farber Cancer Institute, The Life Raft Group
Gastrointestinal Stromal Tumors, GIST
06/26
06/27
NCT03604783: Phase 1, First-in-human Study of Oral TP-1287 in Patients with Advanced Solid Tumors

Terminated
1
74
US
TP-1287
Sumitomo Pharma America, Inc.
Advanced Solid Tumors, Sarcoma, Ewing Sarcoma, Dedifferentiated Liposarcoma, Synovial Sarcoma
01/24
01/24
FHD-609-C-001, NCT04965753 / 2021-001488-25: FHD-609 in Subjects With Advanced Synovial Sarcoma or Advanced SMARCB1-Loss Tumors

Terminated
1
55
Europe, US
FHD-609
Foghorn Therapeutics Inc., Foghorn Therapeutics Inc.
Advanced Synovial Sarcoma
12/23
12/23
PASS, NCT00756665: Prostate Active Surveillance Study

Recruiting
N/A
3000
Canada, US
University of Washington, Canary Foundation, Early Detection Research Network
Prostatic Neoplasms
09/29
09/32
NCT06732440: Subthreshold Vestibular Stimulation as a Strategy for Rehabilitation

Not yet recruiting
N/A
30
US
Subthreshold Vestibular Conditioning, Balance Training
Creighton University, National Institute on Deafness and Other Communication Disorders (NIDCD)
Vestibular Hypofunction, Bilateral Vestibular Hypofunction, Presbyvestibulopathy
12/26
12/26

Download Options